# Vitamine D voorkomt statine-gerelateerde spierklachten niet

*geplaatst 2023-01-01 · Cholesterol · JAMA cardiology · doi 10.1001/jamacardio.2022.4250 · https://hartvaat.nl/2023/01/01/vitamine-d-voorkomt-statine-gerelateerde-spierklachten-niet/*

Gerandomiseerde studie in JAMA Cardiology toonde dat vitamine D-suppletie het risico op statine-gerelateerde spierklachten niet verminderde bij nieuwe statinegebruikers. Dit ontkracht de populaire theorie dat vitamine D-tekort bijdraagt aan statine-intolerantie.

## English: Statin-Associated Muscle Symptoms Among New Statin Users Randomly Assigned to Vitamin D or Placebo.

This randomized study showed that vitamin D supplementation does not reduce the incidence of statin-associated muscle symptoms in new statin users, arguing against routine vitamin D for preventing statin intolerance.

## Abstract (original, from the publication)

IMPORTANCE: Statin-associated muscle symptoms (SAMS) are common and may lead to discontinuation of indicated statin therapy. Observational studies suggest that vitamin D therapy is associated with reduced statin intolerance, but no randomized studies have been reported. OBJECTIVE: To test whether vitamin D supplementation was associated with prevention of SAMS and a reduction of statin discontinuation. DESIGN, SETTING, AND PARTICIPANTS: Men 50 years or older and women 55 years or older, free of cancer and cardiovascular disease, were enrolled in a randomized, placebo-controlled, double-blind clinical trial of vitamin D supplementation. Participants who initiated statin therapy after randomization were surveyed in early 2016. The data were analyzed in early 2022. INTERVENTIONS: Daily cholecalciferol (2000 international units) or placebo with assessment of statin prescriptions during follow-up. MAIN OUTCOMES AND MEASURES: Muscle pain or discomfort lasting several days (primary outcome) and discontinuation of a statin due to SAMS (secondary outcome). RESULTS: Statins were initiated by 1033 vitamin D-assigned participants and 1050 placebo-assigned participants; mean (SD) age was 66.8 (6.2) years and 49% were women. Over 4.8 years of follow-up, SAMS were reported by 317 participants (31%) assigned vitamin D and 325 assigned placebo (31%). The adjusted odds ratio (OR) was 0.97 (95% CI, 0.80-1.18; P = .78). Statins were discontinued by 137 participants (13%) assigned to vitamin D and 133 assigned to placebo (13%) with an adjusted OR of 1.04 (95% CI, 0.80-1.35; P = .78). These results were consistent across pretreatment 25-hydroxy vitamin D levels (interaction P value = .83). Among participants with levels less than 20 ng/mL, SAMS were reported by 28 of 85 vitamin D-assigned participants (33%) and 33 of 95 placebo-assigned participants (35%). For those with levels less than 30 ng/ml, SAMS were reported by 88 of 330 vitamin-D assigned participants (27%) and 96 of 323 of placebo-assigned participants (30%). CONCLUSIONS AND RELEVANCE: Vitamin D supplementation did not prevent SAMS or reduce statin discontinuation. These results were consistent across pretreatment 25-hydroxy vitamin D levels. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01169259.

Auteurs: Mark A Hlatky, Pedro Engel Gonzalez, JoAnn E Manson, Julie E Buring, I-Min Lee, Nancy R Cook, Samia Mora, Vadim Bubes, Neil J Stone

---
Bron: JAMA cardiology, https://doi.org/10.1001/jamacardio.2022.4250. Bijgewerkt 2026-07-03T13:29:14Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.